Enzyme prodrug strategies for cancer therapy:
Gespeichert in:
| Format: | Buch |
|---|---|
| Sprache: | English |
| Veröffentlicht: |
New York [u.a.]
Kluwer Acad. - Plenum Publ.
1999
|
| Schlagworte: | |
| Online-Zugang: | Inhaltsverzeichnis |
| Beschreibung: | XIII, 257 S. Ill., graph. Darst. |
| ISBN: | 0306458950 |
Internformat
MARC
| LEADER | 00000nam a2200000 c 4500 | ||
|---|---|---|---|
| 001 | BV012513513 | ||
| 003 | DE-604 | ||
| 005 | 19990507 | ||
| 007 | t| | ||
| 008 | 990417s1999 xx ad|| |||| 00||| eng d | ||
| 020 | |a 0306458950 |9 0-306-45895-0 | ||
| 035 | |a (OCoLC)39891433 | ||
| 035 | |a (DE-599)BVBBV012513513 | ||
| 040 | |a DE-604 |b ger |e rakddb | ||
| 041 | 0 | |a eng | |
| 049 | |a DE-355 |a DE-12 | ||
| 050 | 0 | |a RC271.A66 | |
| 082 | 0 | |a 616.99/4061 |2 21 | |
| 084 | |a XI 7000 |0 (DE-625)153024:12905 |2 rvk | ||
| 245 | 1 | 0 | |a Enzyme prodrug strategies for cancer therapy |c ed. by Roger G. Melton ... |
| 264 | 1 | |a New York [u.a.] |b Kluwer Acad. - Plenum Publ. |c 1999 | |
| 300 | |a XIII, 257 S. |b Ill., graph. Darst. | ||
| 336 | |b txt |2 rdacontent | ||
| 337 | |b n |2 rdamedia | ||
| 338 | |b nc |2 rdacarrier | ||
| 650 | 4 | |a Antibodies |x therapeutic use | |
| 650 | 4 | |a Antibody-directed enzyme prodrug therapy | |
| 650 | 4 | |a Antibody-enzyme conjugates |x Therapeutic use | |
| 650 | 4 | |a Antigens |x drug effects | |
| 650 | 4 | |a Antineoplastic Agents |x therapeutic use | |
| 650 | 4 | |a Cancer |x Chemotherapy | |
| 650 | 4 | |a Enzymes |x therapeutic use | |
| 650 | 4 | |a Neoplasms |x drug therapy | |
| 650 | 4 | |a Prodrugs | |
| 650 | 4 | |a Prodrugs |x therapeutic use | |
| 650 | 0 | 7 | |a Zielorgan |0 (DE-588)4205824-7 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Cytostatikum |0 (DE-588)4068347-3 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Enzyminduktion |0 (DE-588)4332491-5 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Krebs |g Medizin |0 (DE-588)4073781-0 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Pro-Pharmakon |0 (DE-588)4193853-7 |2 gnd |9 rswk-swf |
| 655 | 7 | |0 (DE-588)4143413-4 |a Aufsatzsammlung |2 gnd-content | |
| 689 | 0 | 0 | |a Krebs |g Medizin |0 (DE-588)4073781-0 |D s |
| 689 | 0 | 1 | |a Cytostatikum |0 (DE-588)4068347-3 |D s |
| 689 | 0 | 2 | |a Pro-Pharmakon |0 (DE-588)4193853-7 |D s |
| 689 | 0 | |5 DE-604 | |
| 689 | 1 | 0 | |a Cytostatikum |0 (DE-588)4068347-3 |D s |
| 689 | 1 | 1 | |a Pro-Pharmakon |0 (DE-588)4193853-7 |D s |
| 689 | 1 | 2 | |a Enzyminduktion |0 (DE-588)4332491-5 |D s |
| 689 | 1 | 3 | |a Zielorgan |0 (DE-588)4205824-7 |D s |
| 689 | 1 | |5 DE-604 | |
| 700 | 1 | |a Melton, Roger G. |e Sonstige |4 oth | |
| 856 | 4 | 2 | |m HBZ Datenaustausch |q application/pdf |u http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=008493795&sequence=000002&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA |3 Inhaltsverzeichnis |
| 943 | 1 | |a oai:aleph.bib-bvb.de:BVB01-008493795 | |
Datensatz im Suchindex
| _version_ | 1823607497001271296 |
|---|---|
| adam_text |
Contents
Chapter 1
Introduction
Richard J. Knox and Roger G. Melton
1. Introduction 1
1.1. The Activity of the Activated Drug 4
1.2. Activation of the Prodrug by Unbound, Circulating Conjugate 5
1.3. Immunogenicity of the Antibody Enzyme Conjugate 5
References 7
Chapter 2
Prodrugs in Cancer Chemotherapy
Tom Connors
1. Introduction 11
2. Uses of Prodrugs in Cancer Chemotherapy 11
2.1. Optimizing Pharmacokinetics and Tissue Distribution 11
2.2. Prodrugs Activated by Tumor Enzymes 19
2.3. Bioreductive Prodrugs 27
3. Clinical Use of Prodrugs 33
References 33
ix
x Contents
Chapter 3
Factors Influencing Tumor Selective Localization of Antibody
Conjugates
M. A. Sims and Roger G. Melton
1. Introduction 39
2. Tumor Physiology 40
2.1. Relevance of Murine Tumor Models 41
2.2. Route of Administration 42
2.3. Vascularization of Tumors 43
2.4. Vascular Permeability of Tumors 45
2.5. Movement of Macromolecules within Tumors 46
2.6. Effect of Tumor Size and Necrosis 46
3. Properties of the Monoclonal Antibody Vector 47
3.1. Affinity for Antigen 47
3.2. Antibody Class and Isotype 48
3.3. Physical Properties of Immunoconjugates 48
3.4. Metabolism of Tumor Bound Immunoconjugates 49
3.5. Clinical Findings with ADEPT Systems 51
3.6. Manipulation of Tumor Physiology 52
3.7. Vascular Targeting 55
4. Tumor Antigens 56
4.1. Heterogeneity of Antigenic Expression 56
4.2. Antigenic Modulation 58
4.3. Membrane Expression and Circulating Antigen 58
4.4. Antigens Potentially Useful for ADEPT Approaches 60
5. Manipulation of Tumor Antigenic Expression 76
6. Evaluation of Antigenic Targets for ADEPT 78
7. In Vitro Cell Culture Problems 79
8. Unforeseen Problems of Specificity 79
References 80
Chapter 4
Enzymes and Prodrugs Used for ADEPT
Richard J. Knox
1. Introduction 97
2. Enzymes and Prodrugs Used for ADEPT 98
2.1. Glucose Oxidase and Xanthine Oxidase 99
2.2. Carboxypeptidase G2 100
Contents xi
2.3. Carboxypeptidase A and B 103
2.4. Aminopeptidase 105
2.5. Alkaline Phosphatase 106
2.6. P Glucuronidase 107
2.7. p Glucosidase 110
2.8. P Lactamase Ill
2.9. Penicillin Amidase 113
2.10. Cytosine Deaminase 115
2.11. Nitroreductases 116
3. Conclusions 122
References 126
Chapter 5
The Design and Synthesis of Prodrugs for Antibody Directed Enzyme
Prodrug Therapy (ADEPT)
P. J. Burke
1. Introduction 133
2. Prodrugs Used in ADEPT 134
2.1. Prodrugs for Carboxypeptidases 134
2.2. Prodrugs for Alkaline Phosphatase 138
2.3. Prodrugs for Glycosidases 139
2.4. Prodrugs for P Lactamases 143
2.5. Prodrugs for Penicillin V/G Amidase 147
2.6. Prodrugs for Nitroreductase 148
2.7. Prodrugs for Cytosine Deaminase 150
3. Summary 151
References 151
Chapter 6
Preparation and Purification of Antibody Enzyme Conjugates for
Therapeutic Applications
Roger G. Melton
1. Introduction 155
2. Production of Antibody Fragments 156
3. Chemical Coupling of Antibodies to Enzymes 159
3.1. Choice of Linkage 159
3.2. Insertion of Maleimide Groups into Proteins 160
»i Contents
3.3. Thiolation of Proteins 162
3.4. Coupling Conditions 164
3.5. Site Specific Coupling of Proteins 165
4. Alternatives to Chemical Coupling 167
4.1. Bispecific Antibodies 168
4.2. Fusion Proteins 168
5. Purification of Conjugates 169
6. Postpurification Modifications 172
7. Future Developments 172
References 173
Chapter 7
Phage Technology for Producing Antibody Enzyme Fusion Proteins
K. A. Chester, Roger G. Melton, and R. E. Hawkins
1. Introduction 179
2. Antibody Targeted Cancer Therapy 180
3. Potential of Engineered Antibodies for Therapy 180
4. Single chain Fv Antibodies 182
4.1. Tumor Penetration and Biodistribution 182
4.2. Avidity of Binding 183
5. The Phage System 185
5.1. Immunogenicity 186
5.2. Affinity 188
5.3. Diversity 188
6. Target Antigens 189
7. Engineered Antibody Enzyme Fusion Proteins in ADEPT 190
8. Practical Considerations 192
9. Conclusions 193
References 193
Chapter 8
Early Clinical Studies with ADEPT
K. D. Bagshawe and M. Napier
1. Introduction 199
2. Initial Clinical Studies 200
2.1. Study Design 200
2.2. Results 201
Contents xiii
3. Second Clinical Study 202
3.1. Study Design 202
3.2. Results 203
4. Conclusions 206
References 207
Chapter 9
Gene Directed Enzyme Prodrug Therapy (GDEPT) of Cancer
Richard J. Knox
1. Introduction 209
2. Why GDEPT? 212
3. Enzymes and Prodrugs Used for GDEPT 213
3.1. Varicella Zoster Virus Thymidine Kinase 213
3.2. Herpes Simplex Virus Thymidine Kinase 216
3.3. Cytosine Deaminase 221
3.4. Cytochrome P450 223
3.5. Carboxypeptidase G2 226
3.6. Nitroreductase 229
3.7. Other Enzymes 234
4. Conclusions 236
References 238
Appendix
Enzymes and Prodrugs Proposed for Cancer Therapy 245
References 249
Index 255 |
| any_adam_object | 1 |
| building | Verbundindex |
| bvnumber | BV012513513 |
| callnumber-first | R - Medicine |
| callnumber-label | RC271 |
| callnumber-raw | RC271.A66 |
| callnumber-search | RC271.A66 |
| callnumber-sort | RC 3271 A66 |
| callnumber-subject | RC - Internal Medicine |
| classification_rvk | XI 7000 |
| ctrlnum | (OCoLC)39891433 (DE-599)BVBBV012513513 |
| dewey-full | 616.99/4061 |
| dewey-hundreds | 600 - Technology (Applied sciences) |
| dewey-ones | 616 - Diseases |
| dewey-raw | 616.99/4061 |
| dewey-search | 616.99/4061 |
| dewey-sort | 3616.99 44061 |
| dewey-tens | 610 - Medicine and health |
| discipline | Medizin |
| format | Book |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>00000nam a2200000 c 4500</leader><controlfield tag="001">BV012513513</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="005">19990507</controlfield><controlfield tag="007">t|</controlfield><controlfield tag="008">990417s1999 xx ad|| |||| 00||| eng d</controlfield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">0306458950</subfield><subfield code="9">0-306-45895-0</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)39891433</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)BVBBV012513513</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">rakddb</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-355</subfield><subfield code="a">DE-12</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RC271.A66</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">616.99/4061</subfield><subfield code="2">21</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">XI 7000</subfield><subfield code="0">(DE-625)153024:12905</subfield><subfield code="2">rvk</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Enzyme prodrug strategies for cancer therapy</subfield><subfield code="c">ed. by Roger G. Melton ...</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">New York [u.a.]</subfield><subfield code="b">Kluwer Acad. - Plenum Publ.</subfield><subfield code="c">1999</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">XIII, 257 S.</subfield><subfield code="b">Ill., graph. Darst.</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">n</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">nc</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Antibodies</subfield><subfield code="x">therapeutic use</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Antibody-directed enzyme prodrug therapy</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Antibody-enzyme conjugates</subfield><subfield code="x">Therapeutic use</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Antigens</subfield><subfield code="x">drug effects</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Antineoplastic Agents</subfield><subfield code="x">therapeutic use</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Cancer</subfield><subfield code="x">Chemotherapy</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Enzymes</subfield><subfield code="x">therapeutic use</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Neoplasms</subfield><subfield code="x">drug therapy</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Prodrugs</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Prodrugs</subfield><subfield code="x">therapeutic use</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Zielorgan</subfield><subfield code="0">(DE-588)4205824-7</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Cytostatikum</subfield><subfield code="0">(DE-588)4068347-3</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Enzyminduktion</subfield><subfield code="0">(DE-588)4332491-5</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Krebs</subfield><subfield code="g">Medizin</subfield><subfield code="0">(DE-588)4073781-0</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Pro-Pharmakon</subfield><subfield code="0">(DE-588)4193853-7</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="655" ind1=" " ind2="7"><subfield code="0">(DE-588)4143413-4</subfield><subfield code="a">Aufsatzsammlung</subfield><subfield code="2">gnd-content</subfield></datafield><datafield tag="689" ind1="0" ind2="0"><subfield code="a">Krebs</subfield><subfield code="g">Medizin</subfield><subfield code="0">(DE-588)4073781-0</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2="1"><subfield code="a">Cytostatikum</subfield><subfield code="0">(DE-588)4068347-3</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2="2"><subfield code="a">Pro-Pharmakon</subfield><subfield code="0">(DE-588)4193853-7</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2=" "><subfield code="5">DE-604</subfield></datafield><datafield tag="689" ind1="1" ind2="0"><subfield code="a">Cytostatikum</subfield><subfield code="0">(DE-588)4068347-3</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="1" ind2="1"><subfield code="a">Pro-Pharmakon</subfield><subfield code="0">(DE-588)4193853-7</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="1" ind2="2"><subfield code="a">Enzyminduktion</subfield><subfield code="0">(DE-588)4332491-5</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="1" ind2="3"><subfield code="a">Zielorgan</subfield><subfield code="0">(DE-588)4205824-7</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="1" ind2=" "><subfield code="5">DE-604</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Melton, Roger G.</subfield><subfield code="e">Sonstige</subfield><subfield code="4">oth</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="m">HBZ Datenaustausch</subfield><subfield code="q">application/pdf</subfield><subfield code="u">http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=008493795&sequence=000002&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA</subfield><subfield code="3">Inhaltsverzeichnis</subfield></datafield><datafield tag="943" ind1="1" ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-008493795</subfield></datafield></record></collection> |
| genre | (DE-588)4143413-4 Aufsatzsammlung gnd-content |
| genre_facet | Aufsatzsammlung |
| id | DE-604.BV012513513 |
| illustrated | Illustrated |
| indexdate | 2025-02-09T19:00:32Z |
| institution | BVB |
| isbn | 0306458950 |
| language | English |
| oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-008493795 |
| oclc_num | 39891433 |
| open_access_boolean | |
| owner | DE-355 DE-BY-UBR DE-12 |
| owner_facet | DE-355 DE-BY-UBR DE-12 |
| physical | XIII, 257 S. Ill., graph. Darst. |
| publishDate | 1999 |
| publishDateSearch | 1999 |
| publishDateSort | 1999 |
| publisher | Kluwer Acad. - Plenum Publ. |
| record_format | marc |
| spelling | Enzyme prodrug strategies for cancer therapy ed. by Roger G. Melton ... New York [u.a.] Kluwer Acad. - Plenum Publ. 1999 XIII, 257 S. Ill., graph. Darst. txt rdacontent n rdamedia nc rdacarrier Antibodies therapeutic use Antibody-directed enzyme prodrug therapy Antibody-enzyme conjugates Therapeutic use Antigens drug effects Antineoplastic Agents therapeutic use Cancer Chemotherapy Enzymes therapeutic use Neoplasms drug therapy Prodrugs Prodrugs therapeutic use Zielorgan (DE-588)4205824-7 gnd rswk-swf Cytostatikum (DE-588)4068347-3 gnd rswk-swf Enzyminduktion (DE-588)4332491-5 gnd rswk-swf Krebs Medizin (DE-588)4073781-0 gnd rswk-swf Pro-Pharmakon (DE-588)4193853-7 gnd rswk-swf (DE-588)4143413-4 Aufsatzsammlung gnd-content Krebs Medizin (DE-588)4073781-0 s Cytostatikum (DE-588)4068347-3 s Pro-Pharmakon (DE-588)4193853-7 s DE-604 Enzyminduktion (DE-588)4332491-5 s Zielorgan (DE-588)4205824-7 s Melton, Roger G. Sonstige oth HBZ Datenaustausch application/pdf http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=008493795&sequence=000002&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA Inhaltsverzeichnis |
| spellingShingle | Enzyme prodrug strategies for cancer therapy Antibodies therapeutic use Antibody-directed enzyme prodrug therapy Antibody-enzyme conjugates Therapeutic use Antigens drug effects Antineoplastic Agents therapeutic use Cancer Chemotherapy Enzymes therapeutic use Neoplasms drug therapy Prodrugs Prodrugs therapeutic use Zielorgan (DE-588)4205824-7 gnd Cytostatikum (DE-588)4068347-3 gnd Enzyminduktion (DE-588)4332491-5 gnd Krebs Medizin (DE-588)4073781-0 gnd Pro-Pharmakon (DE-588)4193853-7 gnd |
| subject_GND | (DE-588)4205824-7 (DE-588)4068347-3 (DE-588)4332491-5 (DE-588)4073781-0 (DE-588)4193853-7 (DE-588)4143413-4 |
| title | Enzyme prodrug strategies for cancer therapy |
| title_auth | Enzyme prodrug strategies for cancer therapy |
| title_exact_search | Enzyme prodrug strategies for cancer therapy |
| title_full | Enzyme prodrug strategies for cancer therapy ed. by Roger G. Melton ... |
| title_fullStr | Enzyme prodrug strategies for cancer therapy ed. by Roger G. Melton ... |
| title_full_unstemmed | Enzyme prodrug strategies for cancer therapy ed. by Roger G. Melton ... |
| title_short | Enzyme prodrug strategies for cancer therapy |
| title_sort | enzyme prodrug strategies for cancer therapy |
| topic | Antibodies therapeutic use Antibody-directed enzyme prodrug therapy Antibody-enzyme conjugates Therapeutic use Antigens drug effects Antineoplastic Agents therapeutic use Cancer Chemotherapy Enzymes therapeutic use Neoplasms drug therapy Prodrugs Prodrugs therapeutic use Zielorgan (DE-588)4205824-7 gnd Cytostatikum (DE-588)4068347-3 gnd Enzyminduktion (DE-588)4332491-5 gnd Krebs Medizin (DE-588)4073781-0 gnd Pro-Pharmakon (DE-588)4193853-7 gnd |
| topic_facet | Antibodies therapeutic use Antibody-directed enzyme prodrug therapy Antibody-enzyme conjugates Therapeutic use Antigens drug effects Antineoplastic Agents therapeutic use Cancer Chemotherapy Enzymes therapeutic use Neoplasms drug therapy Prodrugs Prodrugs therapeutic use Zielorgan Cytostatikum Enzyminduktion Krebs Medizin Pro-Pharmakon Aufsatzsammlung |
| url | http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=008493795&sequence=000002&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA |
| work_keys_str_mv | AT meltonrogerg enzymeprodrugstrategiesforcancertherapy |